LorenDPenaMD
Medical Genetics • Cincinnati, OHClinical Genetics
Assistant Professor, Pediatrics, Duke Univ Sch of Med
Are you Dr. Pena?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 57 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
3333 Burnet Ave
Cincinnati, OH 45229Phone+1 513-636-4760Fax+1 513-636-7297
Summary
- Dr. Loren Pena, MD is a board certified medical geneticist in Cincinnati, Ohio. She is currently licensed to practice medicine in Ohio, Indiana, and Kentucky. She is affiliated with Cincinnati Children's Hospital Medical Center and Christ Hospital.
Education & Training
University of Chicago/Northwestern UniversityResidency, Medical Genetics and Genomics, 2007 - 2009- University of ChicagoResidency, Pediatrics, 2004 - 2007
Northwestern University The Feinberg School of MedicineClass of 2004
Certifications & Licensure
OH State Medical License 2018 - 2026
KY State Medical License 2021 - 2025
IN State Medical License 2021 - 2023
NC State Medical License 2012 - 2018
IL State Medical License 2004 - 2014- American Board of Pediatrics Pediatrics
- American Board of Medical Genetics and Genomics Clinical Genetics and Genomics
Clinical Trials
- A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy Start of enrollment: 2014 Aug 19
- GBE Deficiency (GSD IV and APBD) Natural History Study Start of enrollment: 2015 Dec 01
- Database Of Clinical Data For Individuals With Variants In The IRF2BPL Gene Start of enrollment: 2018 Nov 27
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsInduced pluripotent stem cell (iPSC) modeling validates reduced GBE1 enzyme activity due to a novel variant, p.Ile694Asn, found in a patient with suspected glycogen st...Chie Naito, Karis Kosar, Eriko Kishimoto, Loren Pena, Yilun Huang
Molecular Genetics and Metabolism Reports. 2024-06-01 - 66 citationsSafety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial.Jordi Diaz-Manera, Priya S. Kishnani, Hani Kushlaf, Shafeeq Ladha, Tahseen Mozaffar
The Lancet. Neurology. 2021-12-01 - 1 citationsCorrection: Phenotypic expansion of CACNA1C-associated disorders to include isolated neurological manifestations.Lance H Rodan, Rebecca C Spillmann, Harley T Kurata, Shawn M Lamothe, Jasmine Maghera
Genetics in Medicine. 2021-10-01
Press Mentions
Cyclo Therapeutics Announces Positive Efficacy Data from Extension Protocol with Trappsol® Cyclo™ in Patients with Niemann-Pick Disease Type CJanuary 5th, 2021
Sanofi Genzyme Presents Results from Phase 1/2 Study of Investigational Second-Generation Therapy for Pompe DiseaseMarch 3rd, 2016
